

3rd International Conference and Exhibition on Pharmacovigilance & Clinical Trials

October 27-29, 2014 Hyderabad International Convention Centre, India

Cardiovascular drug safety profile evaluation among urban private hospitals

Ibel C Fredy, Princy Louis Palatty, Iqbal P T, T V Manikandan and R Srinivasan
PES College of Pharmacy, India

Introduction: The pharmacovigilance is on-going, mandatory process among medical college hospitals. The private hospitals organisation is prioritised and structured differently. Regular efficacy and safety evaluations are not conducted as academic research occurs by default in teaching hospitals. This study investigated and collected Adverse Drug Reactions in this site and contrasted with literature from existing studies to draw comparisons and appropriate interventions.

Methodology: This was a cross sectional study observational study design using conventional ADR form from CDSCO and checklist of cardiovascular drug specific adverse reactions which was administered for data collection after necessary formalities for patient recruitment.

Results: There were statistically significant differences in total no of cardiovascular drugs prescribed, the common CVS drugs used, common concomitant drug prescribed. The ADR profile had commonly mild and moderate severity with low incidence of severe adverse event. Naranjo's scale described the causality among the adverse Reaction to the potential drug.

Conclusion: The adverse reaction profile did have large number of reactions but in the milder range. The cautious prescribing of large number of low intensity ADR indicates the discharge of cautious responsibility due to direct liability and awareness due to peer misdemeanours among small circle of professionals that would have severe repercussions on their clientele.

Biography

Ibel C fredy is doing his V year Doctor of pharmacy from Rajiv Gandhi University of Health sciences, Bangalore. He is an active research scholar. He has been a co-author in 2 research articles. He is working on other research related activities. He is a distinction holder for PharmD I, II and III year.

ibelcfredy@gmail.com